Caitlin D. Lowery

AstraZeneca (Japan) — Japan

Medicine · Health Sciences

11h-index458citations35works23.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(14), Cancer therapeutics and mechanisms(11), Cancer, Hypoxia, and Metabolism(5), Lung Cancer Research Studies(5), Chromatin Remodeling and Cancer(5)

Publications35 total

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Journal of Thoracic Oncology·2024· 48 citedOpen Access
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
Journal of Clinical Oncology·2024· 8 cited
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
Clinical Lung Cancer·2024· 13 citedOpen Access
Supplemental Data from The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
2023Open Access
Data from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
2023Open Access
Supplementary Tables 1-5, Supplementary Figures 1-6 from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α
2023Open Access
Supplementary Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9 from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
2023Open Access
Supplementary tables and figures from Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling
2023Open Access
Supplementary Tables 1-5, Supplementary Figures 1-6 from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α
2023Open Access
Data from The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
2023Open Access
Supplementary Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9 from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
2023Open Access
Supplemental Materials and Methods from The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
2023Open Access
Data from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α
2023Open Access
Data from Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling
2023Open Access
Data from The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
2023Open Access
Supplementary tables and figures from Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling
2023Open Access
Data from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α
2023Open Access
Data from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
2023Open Access
Data from Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling
2023Open Access
Supplemental Data from The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Louis F. Stancato(30), Wayne Blosser(28), Michele Dowless(26), Alle B. VanWye(17), Richard P. Beckmann(14), Matthew Renschler(13), Aimee Bence Lin(13), Jennifer R. Stephens(11), Philip W. Iversen(11), Brian P. Rubin(10), Julie Stewart(10), Beverly L. Falcón(8), Jennifer Stephens(8), Jennifer Stephens(7), Philip J. Ebert(7), Xueqian Gong(7), Peter J. Houghton(6), Terry J. Shackleford(6), Yue Webster(6), Jack Dempsey(6)